Safety and efficacy of ultrasound hyperthermia combined with chemotherapy and radical operation for advanced oral squamous cell carcinoma

doi:10.19439/j.sjos.2017.02.022

Abstract

Abstract: PURPOSES: To explore the safety and efficacy of ultrasound hyperthermia combined with chemotherapy and radical operation for advanced oral squamous cell carcinoma (OSCC). METHODS: Nine patients who had definite pathological diagnosis were enrolled in this clinical trail from 2015 to 2016. All patients underwent ultrasound hyperthermia combined with chemotherapy before radical operation. The treatment regime was as follows: Docetaxel and cisplatin (75mg/m²) used on the first day, fluorouracil (750 mg/m²) infused from 1st to 5th day. All patients received 2 cycles of thermo-chemotherapy, the therapeutic temperature was set to be 40-42 ℃, ultrasound hyperthermia was performed for 40 minutes every other day for 5 times. The therapeutic outcomes were evaluated by observation of clinical tumor regression. RESULTS: Of the 9 patients, complete response（CR）was seen in 1 case, partial response (PR) was seen in 3 cases, stable disease（SD）was seen in 5 cases. Complications were not severe and tolerable. CONCLUSIONS: Ultrasound hyperthermia combined with chemotherapy (TPF) may improve the therapeutic effect in advanced OSCC without obvious adverse reactions, and the toxicity and side effects are well tolerated.

Key words: Ultrasound, Hyperthermia, Chemotherapy, Oral squamous cell carcinoma

CLC Number:

R739.8

SHAO Cui-ling, ZHUANG Qian-wei, MENG Jian, GUO Wei, REN Guo-xin, ZHANG Jie, GU Qian-ping, LI Zhi-ping, WANG Xing, GU Jian-min, HAN Kun. Safety and efficacy of ultrasound hyperthermia combined with chemotherapy and radical operation for advanced oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2017, 26(2): 233-236.

References

[1] Agarwal JP, Nemade B, Murthy V, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer [J]. Radiother Oncol, 2008, 89(1): 51-56.
[2] Das S, Thomas S, Pal SK, et al. Hypofractionated palliative radiotherapy in locally advanced inoperable head and neck cancer: CMC Vellore experience [J]. Indian J Palliat Care, 2013, 19(2): 93-98.
[3] Agrawal A, Purandare N, Shah S, et al. Response assessment in metronomic chemotherapy: RECIST or PERCIST ? [J].Indian J Nucl Med, 2014, 29(2): 74-80.
[4] Gomez-Roca C, Koscielny S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development [J]. Eur J Cancer, 2011, 47(17): 2512-2516.
[5] Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison ofLENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 93-98.
[6] Bhargava D, Deshpande A, Sreekumar K , et al. Guidelines of the infectious diseases society of America for the treatment of methicillin-resistnat Staphylococcus aureus infections: as applied to oral and maxillofacial clinical practice [J]. J Maxillofac Oral Surg, 2013, 12(3): 354-358.
[7] Moros EG, Fan X, Straube WL, et al. Numerical and in vitro evaluation of temperature fluctuations during reflected-scanned planar ultrasound hyperthermia [J]. Int J Hyperthermia, 2009, 14(4):367-382.
[8] 翟亮, 孙福成, 蒋继伟, 等. 超声热疗技术的发展与应用 [J]. 中国医疗器械杂志, 2002, 26(4): 281-283.
[9] Pantazis P, Han Z, Wyche J, et al. Schedule-dependent efficiency of thermochemotherapy in vitro with etoposide and heating at 43 degrees C[J]. Anticancer Res, 1999, 19(2A): 995-998.
[10] Stein U, Jurchon K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters [J]. J Biol Chem, 2003, 276(30): 28562-28569.
[11] Mohamed F, Marchettini P, Stuart OA, et a1.Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia [J]. Ann Surg Oncol, 2004, 10(4): 463-468.
[12] 王升志, 何永文, 毛祖彝, 等. 高温诱导BcaCD885颊癌细胞凋亡及检测 [J].口腔颌面外科杂志, 2000, 10(3): 239-242.
[13] Shimura T, Kitagawa M, Yamada T, et al. The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer [J]. Onkologie, 2012, 35(4): 176-183.
[14] AI-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer [J]. Cancer, 2010, 116(11): 2511-2518.
[15] Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients[J].Radiother Oncol, 2009,92(1):4-14.
[16] 羊一飞, 郭伟, 邱蔚六, 等. 超声热疗联合顺铂治疗口腔鳞癌裸鼠移植瘤的实验研究 [J]. 中国口腔颌面外科杂志, 2003, 1(4): 228-232.
[17] 孟箭, 郭伟. 人舌鳞癌裸鼠原位移植模型的建立及其应用价值 [J]. 中国肿瘤, 2000, 9(10): 478-479.
[18] Ressel A, Schmitt O, Weiss C, et al. Therapeutic outcome and side-effects after radiotherapy. chemotherapy and /or hyperthermia treatment of head and neck tumour xenograft [J]. Eur J Cancer, 2002, 38(4): 594-601.
[19] Hoshina H, Takagi R, Tsurumaki H, et al. Clinical result of thermochemoradiotherapy for advanced head and neck cancer [J]. Gan to Kagaku Ryoho, 2001, 28(3): 331-336.